Phase 2 N=14 Treatment

Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes

Diabetes Mellitus, Type 2

Bottom Line

View on ClinicalTrials.gov: NCT04867707 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2025

Primary outcome: Primary: Change in Glycocalyx Integrity-Perfused Boundary Region — -0.0057 micrometers (mcm)

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Zanamivir (Drug)
Age: Adult · 45+ yrs
Sex: All
Sponsor: University of Missouri-Columbia
Primary completion: Oct 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Glycocalyx Integrity-Perfused Boundary Region	-0.0057	—

Summary

The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a therapeutic strategy to restore endothelial function in T2D patients.

Eligibility Criteria

Inclusion Criteria

Men and women with a BMI of 25-39 kg/m2
Ages 45-64 years at randomization.
Diagnosis of T2D classified based on physician diagnosis.
No vulnerable populations (e.g., prisoners, pregnant, children) will be enrolled.

Exclusion Criteria

Cardiovascular disease including myocardial infraction, heart failure, coronary artery disease, stroke
History of chronic renal or hepatic disease
Active cancer
Autoimmune diseases
Immunosuppressant therapy
Hormone replacement therapy
Excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women)
Current tobacco use
Pregnancy (Premenopausal women will be required to complete a urine pregnancy test before participation)
History of asthma or chronic obstructive pulmonary disease.
History of allergic reaction to lactose or milk proteins
Intranasal live attenuated influenza vaccine (LAIV) given within 2 weeks before zanamivir administration or a planned dose within 48 hours after zanamivir administration. Product insert states to avoid zanamivir administration with intranasal live attenuated influenza vaccine (LAIV).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04867707). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.